Live Donor (LDTx) HIV(+) Kidney Transplantation Improves Allograft Survival vs. Deceased Donor (CRD) Transplantation.
Drexel University College of Medicine, Philadelphia
Meeting: 2017 American Transplant Congress
Abstract number: D251
Session Information
Date: Tuesday, May 2, 2017
Session Name: Poster Session D: Living Donor Kidney Transplant II
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall D1
Hahnemann University Hospital has performed 113 kidney transplants in HIV(+) recipients. We sought to analyze the impact of HIV(+) LDTx on allograft survival.
Methods: The HIV(+) transplant population was divided into two cohorts: 10 LDTx and 103 CRD. Immunosuppression consisted of antibody induction (basiliximab (n=112), antithymocyte globulin (n=1,CRD), and concomitant IVIG (n=19, 1 LDTx/18 CRD)), calcineurin-inhibitor, antiproliferatives, and prednisone. Rejection rates and outcome data were analyzed.
Results: Key demographics in Table 1. Donor creatinine in LDTx was statistically lower, but comparable calculated KDRI scores with CRD. Despite similar rejection rates (figure 1), and time to first ACR (LDTx 174+134 days vs. CRD 200+311 days, p=0.39), median graft survival was longer with LDTx (figure 2).
Summary: Living kidney donor transplant offers a superior option for kidney transplant candidates with HIV. Efforts to increase living donation for HIV(+) kidney candidates may improve long term outcomes in HIV(+)transplantation.
| CRD (n=103) | LDTx (n=10) | p-value | |
| Recipient Age (years) | 48+9 | 45+6 | 0.13 |
| Male | 85% | 90% | 0.69 |
| African American | 87% | 60% | 0.38 |
| BMI | 25.5+5.1 | 25.1+5.8 | 0.73 |
| HCV (+) | 42% | 20% | 0.18 |
| Protease Inhibitor based ART | 52% | 50% | 0.88 |
| KDRI | 1.336+0.51 | 1.195+0.27 | 0.64 |
| Donor Age (years) | 37+15 | 43+8 | 0.27 |
| Terminal creatinine (mg/dL) | 1.49+1.13 | 0.83+0.16 | 0.04 |
| HLA mismatch | 4.3+1.5 | 3.4+2.1 | 0.24 |
| HLA DR mismatch | 1.3+0.7 | 1.2+0.9 | 0.77 |
CITATION INFORMATION: Malat G, Lee D, Ranganna K, Talluri S, Levin Mizrahi L, Harhay M, Culkin C, Guy S. Live Donor (LDTx) HIV(+) Kidney Transplantation Improves Allograft Survival vs. Deceased Donor (CRD) Transplantation. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Malat G, Lee D, Ranganna K, Talluri S, Mizrahi LLevin, Harhay M, Culkin C, Guy S. Live Donor (LDTx) HIV(+) Kidney Transplantation Improves Allograft Survival vs. Deceased Donor (CRD) Transplantation. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/live-donor-ldtx-hiv-kidney-transplantation-improves-allograft-survival-vs-deceased-donor-crd-transplantation/. Accessed March 8, 2021.« Back to 2017 American Transplant Congress